中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

8 records (took 0.037 seconds)

    ARMET AS A MARKER FOR CANCER
    2.
    发明申请
    ARMET AS A MARKER FOR CANCER 审中-公开
    ARMET作为癌症的标记

    公开(公告)号：US20140219998A1

    公开(公告)日：2014-08-07

    申请号：US14251788

    申请日：2014-04-14

    Applicant: Roche Diagnostics Operations, Inc.

    Inventor： Markus Roessler ,  Johann Karl ,  Julia Riedlinger ,  Ingo Lindner ,  Michael Tacke

    IPC: G01N33/574

    CPC classification number: G01N33/57488 ,  G01N33/57423 ,  G01N33/57484 ,  G01N2333/475 ,  G01N2800/52

    Abstract: Disclosed is a method aiding in the assessment of cancer. More specifically disclosed is the use of the arginine-rich metastasized in early tumors protein (=ARMET) as a universal marker of different cancer types. ARMET aids in the assessment of pulmonary or lung cancer (LC) or of colon cancer, e.g., of non-small cell lung carcinoma (NSCLC) or colorectal cancer (CRC), but also likely of other specific types of cancer. Such specific cancer types are, e.g., breast, ovary, cervix, head and neck, endometrium, melanoma, bladder, kidney, pancreas, prostate, esophagus, stomach or bile duct cancer. Further disclosed is a method for assessing cancer from a liquid sample, derived from an individual by measuring ARMET in the sample. Measurement of ARMET can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery.

    Abstract translation: 披露了一种有助于评估癌症的方法。 更具体地公开了在早期肿瘤蛋白（= ARMET）中转移的精氨酸富集作为不同癌症类型的通用标记物的用途。 ARMET有助于评估肺或肺癌（LC）或结肠癌，例如非小细胞肺癌（NSCLC）或结肠直肠癌（CRC），但也可能是其他特定类型的癌症。 这些特定的癌症类型是例如乳腺，卵巢，子宫颈，头颈部，子宫内膜，黑素瘤，膀胱，肾，胰腺，前列腺，食管，胃或胆管癌。 进一步公开了一种通过测量样品中的ARMET从个体获得的来自液体样品的癌症的方法。 例如，可以将ARMET的测量用于癌症的早期检测或用于进行手术的患者的监视。

    ARMET AS A MARKER FOR CANCER
    5.
    发明申请
    ARMET AS A MARKER FOR CANCER 审中-公开
    ARMET作为癌症的标记

    公开(公告)号：US20160377625A1

    公开(公告)日：2016-12-29

    申请号：US15259392

    申请日：2016-09-08

    Applicant: Roche Diagnostics Operations, Inc.

    Inventor： Markus Roessler ,  Johann Karl ,  Julia Riedlinger ,  Ingo Lindner ,  Michael Tacke

    IPC: G01N33/574

    CPC classification number: G01N33/57488 ,  G01N33/57423 ,  G01N33/57484 ,  G01N2333/475 ,  G01N2800/52

    Abstract: Disclosed is a method aiding in the assessment of cancer. More specifically disclosed is the use of the arginine-rich metastasized in early tumors protein (=ARMET) as a universal marker of different cancer types. ARMET aids in the assessment of pulmonary or lung cancer (LC) or of colon cancer, e.g., of non-small cell lung carcinoma (NSCLC) or colorectal cancer (CRC), but also likely of other specific types of cancer. Such specific cancer types are, e.g., breast, ovary, cervix, head and neck, endometrium, melanoma, bladder, kidney, pancreas, prostate, esophagus, stomach or bile duct cancer. Further disclosed is a method for assessing cancer from a liquid sample, derived from an individual by measuring ARMET in the sample. Measurement of ARMET can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery.

    Abstract translation: 披露了一种有助于评估癌症的方法。 更具体地公开了在早期肿瘤蛋白（= ARMET）中转移的精氨酸富集作为不同癌症类型的通用标记物的用途。 ARMET有助于评估肺或肺癌（LC）或结肠癌，例如非小细胞肺癌（NSCLC）或结肠直肠癌（CRC），但也可能是其他特定类型的癌症。 这些特定的癌症类型是例如乳腺，卵巢，子宫颈，头颈部，子宫内膜，黑素瘤，膀胱，肾，胰腺，前列腺，食管，胃或胆管癌。 进一步公开了一种通过测量样品中的ARMET从个体获得的来自液体样品的癌症的方法。 例如，可以将ARMET的测量用于癌症的早期检测或用于进行手术的患者的监视。

Patent Agency Ranking